Whilst Clinigen is paying a full price to establish a European platform, the fit is very good. It should make the Clinical Trial Services division more robust and provide a platform to drive the Unlicensed and Commercial Medicines offerings into Europe. Revenue synergies across the group could be material over time. We push through modest EPS upgrades (1%/3%) and increase our TP to 1213p (from 1157p). We remain attracted to the growth opportunity (as highlighted in our Pharma Services sector not ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two acquisitions create European platform
- Published:
02 Oct 2018 -
Author:
Chris Glasper -
Pages:
3
Whilst Clinigen is paying a full price to establish a European platform, the fit is very good. It should make the Clinical Trial Services division more robust and provide a platform to drive the Unlicensed and Commercial Medicines offerings into Europe. Revenue synergies across the group could be material over time. We push through modest EPS upgrades (1%/3%) and increase our TP to 1213p (from 1157p). We remain attracted to the growth opportunity (as highlighted in our Pharma Services sector not ....